Oragenics Inc.
N/A
USD
N/A
N/A
...
Chart
Financials
Description
OGEN Company Description
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
OGEN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view OGEN Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of OGEN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OGEN's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of OGEN in WallStreetBets Daily Discussion
OGEN News
Recent insights relating to OGEN
CNBC Recommendations
Recent picks made for OGEN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in OGEN
Corporate Flights
Flights by private jets registered to OGEN
Our Analysis